1. Home
  2. AIRI vs SNTI Comparison

AIRI vs SNTI Comparison

Compare AIRI & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air Industries Group

AIRI

Air Industries Group

HOLD

Current Price

$2.67

Market Cap

12.3M

Sector

Industrials

ML Signal

HOLD

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.31

Market Cap

10.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRI
SNTI
Founded
1979
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
10.4M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
AIRI
SNTI
Price
$2.67
$0.31
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
25.9K
194.8K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
24.39
77.31
EPS
N/A
N/A
Revenue
$47,921,000.00
N/A
Revenue This Year
$6.43
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.30
$0.29
52 Week High
$3.95
$2.88

Technical Indicators

Market Signals
Indicator
AIRI
SNTI
Relative Strength Index (RSI) 49.42 29.59
Support Level $2.55 N/A
Resistance Level $2.76 $0.40
Average True Range (ATR) 0.09 0.04
MACD 0.01 0.00
Stochastic Oscillator 68.18 7.74

Price Performance

Historical Comparison
AIRI
SNTI

About AIRI Air Industries Group

Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: